Opinion

Video

RSV: Risk Factors and How It’s Spread

Author(s):

Ryan Haumschild, PharmD, MS, MBAWanda Filer, MD, MBA

A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.

Video content above is prompted by the following questions:

  • Who is at risk for respiratory syncytial virus (RSV) and how prevalent is RSV among older adults?
    • What is the mortality rate associated with RSV infections?
  • How is RSV spread and what are the typical symptoms for RSV?
    • How can infected people minimize the spread of RSV?
Related Videos
A panel of 5 experts on RSV
A panel of 4 experts on CLL
A panel of 4 experts on chronic spontaneous urticaria
A panel of 4 experts on chronic spontaneous urticaria
A panel of 4 experts on CLL
Related Content
RSV_Peter Hansen - stock.adobe.com.jpeg
July 2nd 2024

Which Demographic, Environmental Factors Have Higher Risks for RSV Hospitalization?

Pearl Steinzor
Knowledge on respiratory syncytial virus (RSV) risk factors may help inform public health authorities on high-risk populations, researchers suggest.
Vaccine booster concept faded background | MargJohnsonVA - stock.adobe.com
June 26th 2024

Why Are Some Parents Still Hesitant to Vaccinate Their Child Against RSV?

Pearl Steinzor
Increasing knowledge of the vaccine-preventable disease will ultimately improve vaccine uptake among target groups, researchers suggest.
RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com
June 18th 2024

Simultaneous RSV, Influenza Vaccination Found Safe in Patients With High-Risk Heart Failure

Pearl Steinzor
Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).
RSV vaccine | Peter Hansen - stock.adobe.com
June 11th 2024

FDA Approves Expanded Age Indication for RSV Vaccine Arexvy

Pearl Steinzor
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.
Sick child in hospital-Rawpixel.com-stock.adobe.com.jpeg
June 7th 2024

How COVID-19 Has Impacted RSV Epidemiology Among Children in a Hospital Setting

Pearl Steinzor
Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.
FDA approval | Image Credit: MargJohnsonVA - stock.adobe.com
May 31st 2024

Moderna Receives FDA Nod for Single-Dose RSV mRNA Vaccine

Cameron Santoro
The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo